CEO Soon Jae Park, PhD

CEO Soon Jae Park, PhD has over 25 years of experience in R&D of biomedicine. He started working as a senior researcher at LG Chemical and later LG Life Sciences, and successfully developed recombinant biomedicines such as human growth hormone, erythropoietin, and hepatitis vaccine. As a global leader in the field of biosimilars, he succeeded in obtaining the European approval for human growth hormone biosimilar in 2006.
In his later years at LG Life Sciences, he managed overseas business development and partnering, and licensing-out, creating business network with various pharmaceutical and biotech companies and accumulating experiences in business development.
After working at LG Life Sciences, he aided Hanwha Group to begin its antibody biosimilar business by constructing relevant organizations and pipeline. Afterwards, he worked as a professional entrepreneur of Binex, acquiring private-sector operation right to operate KBCC, a consigned biomedicine production facility of Ministry of Knowledge Economy of Korea.
In 2008, he started Alteogen with Dr. Hye-Shin Chung, and was inaugurated as CEO in 2010.
He is acknowledged as one of the leading figures in Korea for R&D and commercialization of biomedicine, as being selected as one of the ‘Top 100 technologies and the people in 60 years of Korean History,’ awarded by National Academy Engineering of Korea in 2010.

Management Board

HangYeon Kim
CFO(Chief Financial Officer), Executive Vice President

He majored in business administration at the university and obtained a certification of KICPA(Korean Certified Public Accountant). He worked at Big 4 accounting firms for 10 years and has various experiences in NPL(Non-performing Loan) and real estate.

Tae-Yon Chun
CAO(Corporate Alliance Officer), Executive Vice President, PhD, JD

Dr. Chun oversees Global Business Development activities at Alteogen. In addition, Dr. Chun leads the IP team making strategies for prosecuting and managing Alteogen’s proprietary technology asset. Dr. Chun received his Ph.D. in Biochemistry (Immunology) and his postdoctoral training in Molecular Endocrinology at the University of Wisconsin-Madison. He also served as a research faculty at Indiana University School of Medicine researching in Cardiovascular and Gastroenterological diseases. After that, he achieved a law degree (J.D.) at Indiana University Robert H. McKinney School of Law. As an U.S. Patent Attorney, Dr. Chun actively practiced his dual backgrounds in a Korean Law and IP consulting firm promoting biotech companies’ domestic and global business development. He also managed several government-funded projects including global biopharma-technology licensing project and IP financing project. Dr. Chun is admitted to practice before the USPTO, Indiana, and District of Columbia.

Vivek Shenoy
CBO(Chief Business Development Officer), PhD, MBA

Vivek B Shenoy brings over 25 years of experience in research and the Pharmaceutical/Biotech arena, with wide global experience in Business Development and Licensing (BD&L), and various Commercial and Development areas ranging from start-up biotechs to large pharma. He received his PhD in Molecular Biology from the University of Florida, and his MBA from the Warrington College of Business. He and his wife live in Newark, Delaware, and they have two grown children.

Kyuwan Kim
Senior Vice President, Head of New Drug Development

Beginning his career as a researcher of LG Chemistry and later LG Life Sciences, Vice President Kyuwan Kim spearheaded R&D and commercialization of mixed vaccine, HIB vaccine, and other vaccines as the leader of vaccine research team. He also led projects for process improvement for human growth hormone, hepatitis B vaccine, and milk promotion hormone, etc.. After 22 years of career at LG Life Sciences, he is in charge of new drug development.

Sang Woo Kang
Senior Vice President, Management Support Group

He started his career at Citibank upon graduating with degree in Biochemistry.

After earning MBA degree, he had worked in Samsung Electronics/Samsung Securities and venture capital, and was in charge of business development and M&A work in bio-venture companies.

He is now also working as member of Small and Medium Business Technology Development Support Project Evaluation Committee in SMTECH.

Since June 2020, he is in charge of Management Support Group at Alteogen.